Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

 Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for the Treatment of Metastatic Pancreatic Cancer

Shots:

  • Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients with metastatic pancreatic cancer
  • The P-III HALO-301 study results: did not meet its 1EPs of OS (11.2 vs 11.5mos.) as there was a higher response rate but it did not translate into an improvement in DOR, PFS or OS
  • The discontinuation of all the development activities for PEGPH20 and allow Halozyme to focus solely on its ENHANZE drug delivery technology

Click here to­ read full press release/ article | Ref: Halozyme | Image: SPJ News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post